SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : ONXX -- Ignore unavailable to you. Want to Upgrade?


To: Darrel McPherson who wrote (175)2/28/1998 3:42:00 PM
From: Jack Be Quick  Read Replies (2) | Respond to of 810
 
Darrel & All,

Came across this Lehman's biotech stock research/rec. area while checking out the LGND thread (coutesy of H. Niman). In the 2/27 Onyx update article they have a few words about Onyx, which they rate as a 2-outperform, with a price target of $25 (for whatever that's worth). They cite upcoming reports on the PI/PII Onyx-15 trials and a partnering agreement on the p53 program as news events that may provide price boosts in 1998.

lehman.com

Cheers,
John